MDACC Study No:2012-0223 ( NCT No: NCT01340794)
Title:A Phase 2 Study of Pazopanib (GW786034) in Patients with Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma
Principal Investigator:Camilo Jimenez
Treatment Agent:Pazopanib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if Votrient (pazopanib)
can help to control metastatic pheochromocytoma or paraganglioma. The safety
of this drug will also be studied.

Pazopanib is designed to block the growth of blood vessels that supply
nutrients needed for tumor growth. This may prevent or slow the growth of
cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Endocrine
Phase of Study:Phase II
Treatment Agents:Pazopanib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:NCI
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Camilo Jimenez
Dept:Endocrine Neoplasia & Hormonal Disorders
For Clinical Trial Enrollment:713-792-2841
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults